Holen Sie sich die Stockscreener-App
15.28
7.02%
-1.155
Schlusskurs vom Vortag:
$16.43
Offen:
$16.27
24-Stunden-Volumen:
247.91K
Relative Volume:
0.33
Marktkapitalisierung:
$1.98B
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-3.62%
1M Leistung:
-18.13%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$15.21
$16.32
1-Wochen-Bereich:
$15.21
$16.63
52-Wochen-Spanne:
$15.15
$28.23
Kailera Therapeutics Inc Stock (KLRA) Company Profile
Firmenname
Kailera Therapeutics Inc
Sektor
Branche
Telefon
508-440-9475
Adresse
180 THIRD AVENUE, WALTHAM
Compare KLRA vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KLRA
Kailera Therapeutics Inc
|
15.28 | 2.13B | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
521.27 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.21 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,006.01 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
137.71 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.29 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
Kailera Therapeutics Inc Stock (KLRA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-05-12 | Eingeleitet | Evercore ISI | Outperform |
| 2026-05-12 | Eingeleitet | JP Morgan | Overweight |
| 2026-05-12 | Eingeleitet | Jefferies | Buy |
| 2026-05-12 | Eingeleitet | Leerink Partners | Outperform |
| 2026-05-12 | Eingeleitet | TD Cowen | Buy |
| 2026-05-12 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Kailera Therapeutics Inc Aktie (KLRA) Neueste Nachrichten
symbol__ Stock Quote Price and Forecast - CNN
Frazier Life Sciences Management L.P. Acquires Shares of 1,100,000 Kailera Therapeutics, Inc. $KLRA - marketbeat.com
Atlas Venture Life Science Advisors LLC Makes New Investment in Kailera Therapeutics, Inc. $KLRA - marketbeat.com
2,919,110 Shares in Kailera Therapeutics, Inc. $KLRA Acquired by Wellington Management Group LLP - marketbeat.com
Kailera Therapeutics (NASDAQ:KLRA) Trading Up 7.9%Here's Why - marketbeat.com
Kailera Therapeutics (NASDAQ:KLRA) Reaches New 1-Year LowShould You Sell? - MarketBeat
Kailera Therapeutics (NASDAQ:KLRA) Trading Down 8.6%Should You Sell? - marketbeat.com
Kailera Therapeutics (NASDAQ:KLRA) Trading 8.6% HigherHere's Why - marketbeat.com
Kailera Therapeutics (NASDAQ:KLRA) Hits New 1-Year LowHere's Why - marketbeat.com
Top Kailera Therapeutics (KLRA) Competitors 2026 - MarketBeat
2 GLP-1 Stocks That Could Double Your Money by 2031 - AOL.com
KLRA Price Today: Kailera Therapeutics, Inc. Stock Price, Quote & Chart | MEXC - mexc.co
Kailera Therapeutics, Inc. (NASDAQ:KLRA) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Hengrui Pharma's Innovative Drug Revenue Share Tops 60% in H1; Two NewCo Partners List on Nasdaq - finance.biggo.com
KLRA Archives - 24/7 Wall St.
Vertex Pharmaceuticals Just Hit an All-Time High. Here's Why the Biotech Stock Could Soar Even More - AOL.com
Kailera Therapeutics: The Record-Breaking Obesity IPO Big Pharma Cannot Ignore - 24/7 Wall St.
Kailera Therapeutics shares dip amid Phase 3 ob... - Pluang
Kailera Therapeutics (NASDAQ:KLRA) Trading 6.6% HigherHere's Why - MarketBeat
Kailera Therapeutics (KLRA) Reports Wider Losses And Names New CTO, Is The Low P B Justified? - Yahoo Finance
Canada Pension Plan (KLRA) discloses 5.6% Kailera Therapeutics ownership in 13G filing - Stock Titan
Jefferies Maintains Kailera Therapeutics(KLRA.US) With Buy Rating, Maintains Target Price $48 - Moomoo
RTW Investments discloses 8.3% Kailera Therapeutics (KLRA) stake on Schedule 13G - Stock Titan
J.P. Morgan Maintains Kailera Therapeutics(KLRA.US) With Buy Rating, Maintains Target Price $30 - Moomoo
TD Cowen Maintains Kailera Therapeutics(KLRA.US) With Buy Rating, Maintains Target Price $57 - Moomoo
KLRA SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocus
William Blair Maintains Kailera Therapeutics(KLRA.US) With Buy Rating - Moomoo
KAILERA THERAPEUTICS ($KLRA) Releases Q2 2026 Earnings - Quiver Quantitative
Kailera Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Kailera Q2 loss widens 285% to $111.3M on R&D surge; cash runway extends to mid-2028 - scanx.trade
Kailera Therapeutics Submits Q2 2026 10-Q Highlighting Financial Status and Operational Risks - Kalkine Media
Form 8K Kailera Therapeutics For: 12 August By Investing.com - Investing.com Australia
Kailera Therapeutics, Inc. 2Q 2026: Revenue N/A, Net loss $(111.3M), EPS $(1.09) — 10-Q Summary - TradingView
KLRA: Q2 net loss rose to $111.3M on higher R&D; $1.17B cash post-IPO funds operations into mid-2028 - tradingview.com
Kailera Reports Second Quarter 2026 Financial Results and Provides Business Updates - The Manila Times
KAILERA THERAPEUTICS ($KLRA) Releases Q2 2026 Earnings | KLRA Stock News - quiverquant.com
Kailera Therapeutics, Inc. Announces Appointment of Nur Nicholson as Chief Technology Officer, Effective August 31, 2026 - marketscreener.com
Kailera Therapeutics Appoints Nur Nicholson as Chief Technology Officer - The Manila Times
Obesity focused Kailera appoints Nur Nicholson as CTO - The Pharma Letter
Kailera Therapeutics Inc expected to post a loss of 75 cents a shareEarnings Preview - TradingView
Jiangsu Hengrui discloses 8.9% Kailera Therapeutics (KLRA) stake in ownership filing - Stock Titan
Bain Capital Xiv General Partner, Llc Net Worth (2026) - GuruFocus
Kailera Therapeutics, Inc. Revenue Breakdown – NASDAQ:KLRA - TradingView
Kailera Therapeutics (KLRA) Stock Price, News & Analysis $KLRA - MarketBeat
Patent fight erupts around next generation of multibillion-dollar GLP-1 weight-loss drugs - The Business Journals
Yuting Liu Net Worth (2026) - GuruFocus
Jamie Beth Coleman Net Worth (2026) - GuruFocus
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Net Worth (2026) - GuruFocus
Parabilis tops Kailera as biopharma IPOs surge to best H1 since 2021 - BioWorld News
Scott M. Wasserman Net Worth (2026) - GuruFocus
Stuart Partners, Llc Net Worth (2026) - GuruFocus
Finanzdaten der Kailera Therapeutics Inc-Aktie (KLRA)
Es liegen keine Finanzdaten für Kailera Therapeutics Inc (KLRA) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
Kailera Therapeutics Inc-Aktie (KLRA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| RTW INVESTMENTS, LP | 10% Owner |
Apr 20 '26 |
Buy |
16.00 |
500,000 |
8,000,000 |
10,776,820 |
| BAIN CAPITAL INVESTORS LLC | 10% Owner |
Apr 20 '26 |
Buy |
16.00 |
8,398,438 |
134,375,008 |
26,255,581 |
| Koppel Adam | Director |
Apr 20 '26 |
Buy |
16.00 |
1,562,500 |
25,000,000 |
22,583,268 |
| Bain Capital Life Sciences Inv | 10% Owner |
Apr 20 '26 |
Buy |
16.00 |
1,562,500 |
25,000,000 |
22,583,268 |
| Kaplan Andrew T. | Director |
Apr 20 '26 |
Buy |
16.00 |
8,398,438 |
134,375,008 |
26,255,581 |
0.71%
2.84%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):